KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
COLLEGE OF SCIENCE
DEPARTMENT OF BIOCHEMISTRY AND BIOTECHNOLOGY
NAME: AMANKWAH EMMANUELLA AMPONSAH
INDEX NUMBER: 3165922
PROGRAMME: BSc BIOCHEMISTRY
CLASS: BIOCHEM 3
DATE: 6TH FEBRUARY,2025
COURSE: MOLECULAR GENETICS (BCHEM 365)
TITLE: DEMONSTRATING HOW GENE THERAPY TECHNOLOGY HAS IMPACTED THE TREATMENT OF
GENETIC DISEASES SUCH AS SICKLE CELL DISEASE.
ABSTRACT
Gene therapy has become a revolutionary means of treating genetic disorders by addressing the root
molecular causes. This paper looks at the molecular genetics of gene therapy and its implications in
treating disorders such as sickle cell disease. Gene therapy has emerged as a good alternative to
traditional treatment methods through gene addition, gene editing, and stem cell therapy. Recent
advancements in CRISPR-Cas9 and lentiviral vector technologies have brought in possibilities of curative
solutions to sickle cell disease by correcting the defective hemoglobin gene. (Zhang, 2023). Despite
challenges such as safety, accessibility, and long-term efficacy, the success of gene therapy trials justifies
it in the medical world. This paper discusses the scientific principles, therapeutic applications, and future
prospects of gene therapy in addressing genetic disorders. It emphasizes its potential in revolutionizing
patient care and disease management.
INTRODUCTION
At the global level, “it is estimated that about 7% of the population are carriers of inherited haemoglobin
disorders and 300,000 to 400,000 babies with severe forms are born each year”. (Weatheral and Clegg,
2001). Every day is a struggle against acute severe painful crises, frequent visits to the hospital, and the
emotional burden of a disease that annually appears in the world in the amount of about 300,000
newborns. It is also important to note that these figures are not just statistics, but the lives of entire
families who are struggling with the problem of a genetic disorder every day.
Sickle cell disease is a genetic disorder that is usually characterized by the abnormal shape (sickle shape)
of the red blood cells caused by a defect in a single gene, specifically the hemoglobin B gene, which
provides instructions for making a part of hemoglobin. This defect leads to the production of abnormal
hemoglobin called hemoglobin S. When the red blood cells containing hemoglobin S get deoxygenated,
they usually take on a rigid sickle shape which causes blockages in blood vessels leading to serious and
various complications like painful crises requiring emergency care, anxiety, depression, and feelings of
isolation among patients and their families. Traditional treatments (pain management, blood transfusions,
and hydroxyurea), which are sometimes helpful, often fall short. These treatments have been supportive,
but they do not resolve the underlying genetic issue. (Rees, Williams, and Gladwin, 2010). Gene therapy
presents a revolutionary advancement in the treatment and potential cure for sickle cell disease, as it
directly addresses the alteration in genes responsible for the disorder and offering new hope for patients
by not only alleviating symptoms and reducing complications but also potentially transforming sickle cell
disease from a chronic condition into a manageable or curable one (Tisdale, J. F., et al. 2018). It is
possible to edit the faulty gene that causes SCD so that patients can have a future full of good health and
better quality of life. Clinical trials are currently going on and CRISPR-Cas9 has been tested and was
successful. Patients could have a normal hemoglobin and could reduce or completely rid themselves of
SCD symptoms. (U.S. Food and Drug Administration,2023). This breakthrough in medical treatment is
for everyone who has SCD to be cured.
We are at the cusp of a medical revolution. The aspiration is that gene therapy could change sickle cell
disease from a life-long affliction to a relic, where people affected can live without the shadows of pain.
SICKLE CELL DISEASE
“Herrick studied at various hospitals and taught. The first time he discovered sickle-shaped red blood
cells in 1910, when he was studying a blood film of a dental student from Grenada. Herrick described the
student's disease, which was named Herrick syndrome for many years and now is called sickle-cell
disease. This disease is common in West Africa”. (Herrick, 1910). A collection of hereditary conditions
known as sickle cell disease, or sickle cell anemia, affects hemoglobin, the main protein in red blood cells
that delivers oxygen. Red blood cells often have a disc-like shape and can flex to pass through blood
vessels. Red blood cells with sickle cell disease have an irregular form, usually crescent or "sickle," as a
result of a gene mutation that alters the hemoglobin molecule. “Red blood cells that sickle can obstruct
blood flow to the rest of the body because they are difficult to bend or move”. (National Heart, Lung, and
Blood Institute,2024).
Individuals with one usual hemoglobin gene and one sickle cell gene (HbAS) have a sickle cell trait,
which commonly does not cause symptoms but can be transferred to descendants. The condition
originates from a single nucleotide swap in the HBB gene (which encodes the beta-globin subunit of
hemoglobin). The mutation switches adenine (A) with thymine (T), leading to the substitution of valine
for glutamic acid at the sixth position of the beta-globin chain. This change causes hemoglobin to
polymerize under low oxygen conditions, altering the shape of red blood cells. (Ingram,1957).
Common Symptoms of Sickle Cell Disease

Pain Crises: Also known as Vaso-occlusive crises.

Anemia

Organ Damage: acute chest syndrome, stroke, organ failure
Some treatments of sickle cell disease include:
1. Pain Management (medications and adjunct therapies like physiological therapies)
2. Blood Transfusions
3. Hydroxyurea
Since each of the aforementioned therapies has certain drawbacks, they cannot be considered cures or
permanent solutions. Current sickle cell disease treatments have limitations even though they can greatly
enhance quality of life and lower complications. Research on creating new treatments, such as gene
therapy and innovative drugs, is still ongoing to address these issues and enhance the prognosis of people
with sickle cell disease.
GENE THERAPY.
The majority of our body’s genetic conformation is stored in 23 pairs of chromosomes inside the nucleus
of the cell. Each chromosome is made up of DNA, which stores information to determine our unique
characteristics. specific section of the DNA is called a gene. The human body has approximately 20000 to
25000 genes, with each person having two copies of each gene, one from each biological parent. Genes
provide instructions on how proteins are made, which is essential for the body's work. (National Human
Genome Research Institute, 2025). A small change to the DNA within our genes can alter how the
proteins and our body functions. Gene changes or variants happen to everyone through age, exposure to
certain chemicals, or from the environment. These changes can be passed from parents to offspring; some
of the body can repair itself, and others cannot, which leads to genetic disorders or diseases where
treatment will be required. Gene therapy aims to help correct these mutations leading to diseases by
addressing the underlying cause of the disease. (Christoffersen,2020). Gene therapy is a progressive
approach to treating or preventing diseases by altering the genes inside a patient's cells. The purpose is to
address the implicit genetic cause of a disease rather than just treating its symptoms. By correcting or
replacing faulty genes, gene therapy has the potential to cure genetic disorders, improve resistance to
diseases, and even fight some forms of cancer. The genetic material used or targeted is the DNA or RNA.
DNA stores our genetic information whilst RNA is a modified copy of that information needed for the
cells to build the correct proteins. In this technique, the genetic material is transferred to the cell and
changes how proteins are produced by the cell. It can reduce the levels of certain disease-causing proteins,
increase the production of working proteins or even produce new or modified proteins within the cell. to
deliver the new or modified genetic material to the cell, it needs a package or a container to send it to the
cell, typically referred to as a vector. (Nóbrega, Mendonça, and Matos, 2020). Most of the time, viruses
are used as the vectors because of their ability to easily get into cells. These viruses have been modified to
prevent causing disease when they enter the human body to deliver the therapeutic genetic material.
Gene therapy can be administered in two ways, in vivo and ex vivo. In in vivo, the gene is directly
introduced in the person through injection. In ex vivo, a cell is removed from the patient and the
appropriate modifications are made to it and sent back into the patient’s body. (American Society of Gene
and Cell Therapy,2018).
One of the most significant advancements in gene therapy has been the development of gene editing
technologies, most notably CRISPR-Cas9. This powerful tool allows scientists to make precise changes
to the DNA of living organisms. “CRISPR-Cas9 consists of two key components: a guide RNA that
locates the target DNA sequence and the Cas9 enzyme that cuts the DNA at the specified location”. (Bak,
Gomez-Ospina, and Porteus, 2018).
How Gene Therapy Works.
Gene therapies typically involve the following.
1. Gene Identification: Scientists determine which particular gene is in charge of the illness or
malfunction in question.
2. Mechanism of Delivery: The patient's cells are modified to incorporate the therapeutic gene. Several
delivery mechanisms can be used to do this, including:

Vectors: Usually made from viruses, vectors are altered to include the therapeutic gene without
endangering the patient.

Physical techniques: Direct gene introduction into cells can also be accomplished by technologies
like electroporation, which uses electrical pulses.
3. Gene Editing Technologies: The creation of gene editing technologies, particularly CRISPR-Cas9, has
been one of the most important developments in gene therapy. With the use of this potent instrument,
researchers may precisely alter living things' DNA: o CRISPR-Cas9: The two main parts of this method
are the Cas9 enzyme, which cuts the DNA at the designated spot, and a guide RNA, which finds the target
DNA sequence. Following cutting, the gene can be altered by either introducing a new gene or fixing a
mutation by using the cell's built-in repair systems.
4. Therapeutic Outcomes: After the gene is delivered and edited, the goal is to either repress damaging
genes or allow the cells to create the required proteins, which will ultimately enhance health. (Duan et al,
2021).
Brief History of Gene Therapy Development.
The foundational ideas of gene therapy date back to the 1960s, but it wasn’t until the late 1980s that
researchers began to explore practical applications. Initial experiments focused primarily on the
modification of cells in laboratory conditions. The first gene therapy trial was conducted in 1990 when a
baby girl named Ashanti DeSilva received treatment for adenosine deaminase deficiency (ADA
deficiency), a rare genetic disorder that affects the immune system. This trial marked a significant
milestone in gene therapy (Ananya, 2023). The field faced serious setbacks when an 18-year-old patient,
Jesse Gelsinger, died during a gene therapy trial for ornithine transcarbamylase deficiency. His death
raised ethical concerns and highlighted the risks associated with gene therapy, leading to increased
scrutiny and regulatory measures. Following the setbacks, regulatory bodies established stricter guidelines
for gene therapy research. However, the 2000s also saw the emergence of successful trials, notably in
treating inherited eye diseases like Leber's congenital amaurosis. The CRISPR-Cas9 technique has also
transformed the field, leading to innovative research and therapies (Rinde,2019). Gene therapy remains a
rapidly evolving area of medicine, with ongoing research aimed at broadening its applications and
improving safety and efficacy. The promise of treating previously untreatable genetic disorders continues
to inspire both researchers and patients. The journey of gene therapy has been fascinating, marked by both
groundbreaking successes and notable setbacks.
GENE THERAPY AND SICKLE CELL DISEASE.
Sickle cell disease, as mentioned earlier, is a genetic disorder inherited from parents due to a defect in a
single gene, specifically the HbB gene, which provides instructions for producing a part of hemoglobin. It
leads to various problems, including vaso-occlusive events, infections, organ damage, and may result in
death. Gene therapy offers a groundbreaking approach to potentially cure or significantly alleviate the
effects of this Sickle cell disease through approved approaches like CASGEVY (the first approved
therapy in the USA that uses CRISPR) and LYFGENIA. (U.S. Food and Drug Administration,2023)
There are various ways of applying gene therapy in treating sickle cell disease, some of these methods
include gene addition, gene editing, and gene silencing.
Mechanisms of Action
Gene therapy for Sickle Cell Disease aims to address the root genetic cause—mutations in the HBB
gene that encodes the beta-globin subunit of hemoglobin. Here are two primary mechanisms by which
gene therapy targets SCD:
Gene Editing: In gene editing, there is the permanent modification of disease-causing genes through
precise correction, deletion, addition, and disruption of specific sequences. “Several gene editing
strategies for curing SCD have shown promise in recent preclinical studies, including, correction of the
causative point mutation in HBB, induction of fetal hemoglobin (HbF) via gene-disruption of γ-globin
(HBG) repressors, and induction of HbF via introducing beneficial hereditary persistence of fetal
hemoglobin (HPFH) mutations on the β-globin locus, CRISPR-Cas9 is used to edit the gene responsible
for producing the problematic beta-globin”. (Park and Bao,2021). The approach involves cutting the
DNA at the location of the HBB gene mutation and introducing corrective sequences that can either
restore normal beta-globin production or promote the expression of fetal hemoglobin (HbF), which can
replace the defective adult hemoglobin (HbS). Increasing HbF levels can lead to fewer sickle-shaped cells
and lessen the severity of sickle cell crises. (Magis, DeWitt Wyman, Vu, Heo, Shao, et al 2019). Two key
elements that are used by CRISPR Cas 9 are the RNA fragment known as guide RNA and the protein
known as the Cas enzyme or nuclease. “The guide RNA locates the DNA code sequence that needs to be
changed, while the Cas enzyme or nuclease cuts and modifies DNA at the site specified by the RNA”.
(Bak, Gomez-Ospina, and Porteus, 2018).

Gene Addition: Another promising approach delivers a corrected copy of the HBB gene into the
patient’s hematopoietic stem cells (HSCs). This is usually accomplished via a viral vector. The
corrected gene can be transcribed and translated into functional beta-globin, promoting normal
red blood cell morphology and function.

Gene Silencing: In gene silencing, a gene is delivered that silences the BCL11A gene or prevents
it from working. The BCL11A gene typically acts as an “off” switch in our body and stops the
production of fetal hemoglobin after a person is born. Silencing this gene will allow the body to
produce fetal hemoglobin once again. (American Society of Gene and Cell Therapy,2018). Note
that fetal hemoglobin is similar to healthy adult hemoglobin because it can carry oxygen
efficiently in the red blood cells.
Recent Advances and Clinical Trials
There have been some breakthroughs in gene therapy of Sickle Cell Disease in the recent past. Here are
some of the key studies and the results showing the safety and efficacy of it.

Clinical Trials with LentiGlobin: This therapy involves collecting a patient's HSCs and
modifying them to express a functional form of the beta-globin gene using a lentiviral vector.
Early-phase trials have demonstrated that patients treated with LentiGlobin have shown
substantial increases in HbF levels and significant reductions in vaso-occlusive crises. (Thompson,
Alexis, et al. 2018).

CRISPR-Cas9 Trials: Trials involving CRISPR-Cas9, like the one conducted by researchers at
Harvard and Boston Children's Hospital, reported successful outcomes in patients by dramatically
reducing the proportion of sickled cells. In one study, a treated patient maintained normal
hemoglobin levels with no signs of disease-related symptoms six months after treatment. (Orkin
& Sankaran, 2025).
Multiple clinical studies are aimed at refining the accuracy and safety of gene editing. The vectors
and the editing process are iteratively refined. The focus is on reducing off-target effects. This
strategy is expected to improve patient outcomes.
The rise of gene therapy for Sickle Cell Disease (SCD) brings forth a range of ethical and societal
concerns:
1. Access and Equity: As gene therapies tend to be expensive, there are significant concerns about
equitable access among diverse populations, especially in low-income or underserved
communities. Questions arise regarding how to ensure that all patients, regardless of their
socioeconomic status or geographical location, can benefit from these innovative treatments.
2. Long-term Effects: The long-term effects of gene therapy are still under investigation, and there
are concerns about potential unforeseen consequences or side effects that might emerge years
after treatment. Ethical considerations also include obtaining informed consent, especially when
treatments involve altering genetic material, necessitating a thorough understanding by patients
and their families regarding risks and potential outcomes.
3. Stigmatization and Identity: The possibility of genetic interventions might lead to societal
stigmas around hereditary disorders. Questions about personal identity may arise as patients
choose to alter their genetic makeup, potentially leading to larger discussions about what it means
to have a genetic disorder.
(Gusmano & McCormick, 2024).
CONCLUSION
Gene therapy represents a transformative approach in the treatment of Sickle Cell Disease, fundamentally
aiming to correct the underlying genetic defects rather than merely managing symptoms. The mechanisms
by which these therapies operate, through gene editing, gene silencing and gene addition techniques,
highlight their potential to significantly improve patients’ quality of life. Recent clinical trials have shown
promising results, illustrating the therapy's safety and efficacy through real-world case studies.
As the research progresses, there is hope that gene therapy may improve sickle cell disease and possibly
other conditions. Living in a world free from the misery caused by sickle cell disease is becoming a more
realistic ideal thanks to recent advancements. To ensure that these novel treatments truly benefit everyone
who needs them, more discussions on how to make these discoveries ethical and inexpensive are required
REFERENCES

American Society of Gene and Cell Therapy. (2018). ASGCT 21st annual meeting abstracts,
molecular therapy. Vectors 101 ASGCT - American Society of Gene & Cell Therapy.

Bak, R. O., Gomez-Ospina, N., and Porteus, M. H. (2018). Gene editing on center stage. Trends
in Genetics, pp. 600–611.

Christoffersen, H. M. (2020). Gene mutations: Causes and effects, p. 75, Nova Science Publishers.

Duan, L., Ouyang, K., Xu, X., Xu, L., Wen, C., Zhou, X., Qin, Z., Xu, Z., Sun, W., and Liang, Y.
(2021). Nanoparticle delivery of CRISPR/Cas9 for genome editing. Frontiers in Genetics.

Gusmano, M. K., and McCormick, J. B. (2024). Addressing gene therapy’s ethical and policy
challenges. The Hastings Center.

Herrick, J. B. (1910). Peculiar elongated and sickle-shaped red blood corpuscles in a case of
severe anemia. Archives of Internal Medicine, pp 517-521.

Ingram, V. M. (1957). Gene mutations in human hemoglobin: The chemical difference between
normal and sickle cell hemoglobin. Nature, pp 326-328.

Magis, W., DeWitt, M. A., Wyman, S. K., Vu, J. T., Heo, S.-J., Shao, S. J., et al. (2019). Highlevel correction of the sickle mutation amplified in vivo during erythroid differentiation.

Meir, R. (2019). The death of Jesse Gelsinger, 20 years later. WHYY, Philadelphia.

Miller, J. I., Hassell, K. L., Kellar-Guenther, Y., Quesada, S., West, R., and Sontag, M. (2024).
Public health surveillance of sickle cell disease. JMIR Public Health Surveillance, p 10.

National Heart, Lung, and Blood Institute. (2024). Sickle cell disease. National Institutes of
Health. Retrieved from https://www.nhlbi.nih.gov/health/sickle-cell-disease.

National Human Genome Research Institute. (n.d.)(2025). A brief guide to genomics. National
Institutes of Health.

Nóbrega, C., Mendonça, L., and Matos, C. A. (2020). A handbook of gene and cell therapy.
Springer.

Orkin, S. H., and Sankaran, V. G. (2025). Creating the world’s first CRISPR medicine for sickle
cell disease. Harvard Medicine News, Harvard Medical School.

Park, S. H., and Bao, G. (2021). CRISPR/Cas9 gene editing for curing sickle cell disease.
Transfusion and Apheresis Science: Official Journal of the World Apheresis Association & the
European Society for Haemapheresis, p60. https://doi.org/10.1016/j.transci.2021.103060.

Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010). Update on sickle cell disease. The Lancet,
pp 2018-2031.

Thompson, A. A., et al. (2018). Current results of Lenti globin gene therapy in patients with
severe sickle cell disease treated under a refined protocol in the phase 1 HGB-206 study. Blood,
American Society of Hematology, Abstract 1026.

Tisdale, J. F., et al. (2018). Gene therapy for sickle cell disease—Reversal of sickling. The New
England Journal of Medicine, pp 248-261.

U.S. Food and Drug Administration. (2023, December). FDA approves first gene therapies to
treat patients with sickle cell disease. Retrieved from https://www.fda.gov/news-events/pressannouncements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease.

Weatherall, D. J., and Clegg, J. B. (2001). The thalassemia syndromes. Blackwell Science,
Oxford (UK).

Zhang, S. (2023). The CRISPR era is here. The Atlantic.